Members/Non-Members must be signed in to register for an event.

Sign In

MassBio Partnering Week 2022

September 19, 2022 9:00 AM - September 22, 2022 5:00 PM

Virtual

Add to Calendar 9/19/2022 9:00:00 AM 9/22/2022 5:00:00 PM MassBio Partnering Week 2022 MassBio’s Partnering Week is a week-long event where major biopharmaceutical, medical device, diagnostic, and digital health organizations connect with leading early-stage companies and academic innovators in the life sciences that are developing relevant breakthrough technologies. Each day of September 19 - 22, a new biopharma (Astellas, AstraZeneca, EMD Serono, Takeda) will present on its innovation strategy and therapeutic focus areas, followed by a Q&A and networking with participants. Following the presentations, company leaders will then meet 1:1 with selected companies and technology transfer offices to discuss partnering opportunities.
Register for the Networking Reception on September 20.

Astellas

Astellas is relentless in their pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. They are committed to the realization of greater view by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.


AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. 
 

EMD Serono, Inc.

EMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada -aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono’s global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,500 employees around the country with commercial, clinical and research operations in Massachusetts.
 

Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan with a global U.S. headquarters hub located in Massachusetts. Takeda is committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We aim to accelerate the development of breakthrough science by combining the innovation and cutting-edge discoveries of our partners and groups with Takeda R&D's deep therapeutic area expertise, strong translational capabilities, and asset development strategy. At Takeda R&D’s Center for External Innovation, our unique model supports diverse and flexible partnerships to harness innovation across the discovery and development lifecycle.

 Virtual,